Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel

Eur Urol Focus. 2018 Mar;4(2):153-162. doi: 10.1016/j.euf.2018.05.010. Epub 2018 Jun 18.

Abstract

Context: Cancer development after kidney transplant (KT) has become a major problem, and currently, it is one of the primary causes of death in this population. Urological cancers after KT such as prostate cancer (PCa) have also increased, partly due to the increasing age of recipients and prolonged survival. PCa is the second most commonly diagnosed cancer in men, accounting for 15% of all cancers. Managing localised PCa after KT remains challenging because of treating an immunosuppressed patient with a kidney graft in the pelvic cavity. Several papers reporting PCa treatment after KT have been published. Merging all the available data and summarising most important evidence could be useful for scientific community involved in this issue.

Objective: To systematically review all the available evidence in literature regarding the management of localised PCa after KT.

Evidence acquisition: Computerised bibliographic search of Medline, Embase, and Cochrane databases was performed for all studies reporting outcomes of localised PCa diagnosed in KT patients undergoing curative treatments, including surgery, external beam radiotherapy (EBR) and brachytherapy.

Evidence synthesis: In total, 41 studies included 319 patients with localised PCa after KT. Their mean age was 61.8 (range, 47-79) yr and mean time from KT to PCa was 122 (range, 2-336) mo. Mean prostate-specific antigen was 8.5 (range, 0.3-82), most frequent biopsy Gleason score was 3+3 (50.5%), 62.1% were cT1-cT2, and 56.1% belonged to low-intermediate D'Amico-risk groups. Surgery was performed in 82.1%. After mean follow-up of 33 (range, 1-240) mo, cancer-specific survival at 5 yr was 97.5%, 87.5%, and 94.4% after surgery, EBR, and brachytherapy, respectively.

Conclusions: Radical prostatectomy is the preferred treatment of localised PCa after KT. Overall oncological outcomes do not seem to be worse than general population when performed in referral centres. Other curative treatments such as EBR or brachytherapy were less frequently used; however, brachytherapy showed promising results in a small number of patients. Further better-quality studies should help to clarify the optimal method of managing localised PCa after KT.

Patient summary: Localised PCa after KT seems to have similar oncological outcomes after curative treatments than in general population, with surgery being the most common option for treatment.

Keywords: Brachytherapy; Kidney transplant; Prostate cancer; Radical prostatectomy; Radiotherapy; Renal transplantation; Systematic review.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Aged
  • Brachytherapy / methods
  • Brachytherapy / statistics & numerical data
  • Humans
  • Immunosuppression / adverse effects
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / mortality
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prostate-Specific Antigen / blood
  • Prostatectomy / methods
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery*
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Substances

  • Prostate-Specific Antigen